Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

Amgen (AMGN) is presented as a cheaper alternative to Eli Lilly, trading at a forward P/E of ~16 versus Lilly’s ~32; Lilly is the largest healthcare company (~$950 billion market cap) after a roughly 400% five‑year rally while Amgen has risen ~34% over the same period. Amgen’s GLP‑1 candidate MariTide (phase 3) has produced up to ~20% weight loss at 52 weeks and could be dosed monthly or potentially quarterly (per CEO Bob Bradway), a potential catalyst in a GLP‑1 market projected to exceed $150 billion within a decade that could materially improve Amgen’s upside.

Analysis

Market structure: A quarterly/bi-monthly injectable like Amgen's MariTide (phase‑3) can shift demand away from weekly injectables (LLY's Mounjaro/Zepbound) for a meaningful patient subset, pressuring share and net prices over a multi-year adoption curve in a ~>$150bn TAM. Winners: AMGN, contract manufacturers, labs and payers that can negotiate preferred dosing tiers; losers: smaller GLP‑1 pure‑plays and any incumbent with single-format dependence. Cross-asset: positive idiosyncratic skew for AMGN equity and options IV; modestly negative for long-duration pharma bonds if pricing competition compresses margins and raises credit risk for smaller players.

Risk assessment: Key tail risks are FDA label restrictions (cardio/psychiatric), adverse phase‑3 surprises, manufacturing yield shortfalls, and accelerated payer carve‑outs that force steep net price declines (>20–40%). Immediate (days) volatility will track PR/data windows; short (6–18 months) depends on phase‑3 readouts and filings; long (2–5 years) on real‑world adherence and reimbursement. Hidden dependency: commercial execution — quarterly dosing reduces physician touchpoints and shifts marketing spend to payer deals, not direct DTC.

Trade implications: Direct: asymmetric long in AMGN (valuation 16x forward vs LLY 32x) with a 12–18 month horizon targeting +20–30% rerating if positive MariTide data; pair trade long AMGN / short LLY to neutralize GLP‑1 market risk. Options: buy AMGN 18‑month LEAP 15–25% OTM calls or a 12‑month call spread to cap premium, and hedge with short LLY calls/put spreads to fund cost. Rotate 3–5% portfolio weight from pure obesity small caps into large-cap diversified biotech/healthcare staples.

Contrarian angles: Consensus underestimates commercialization risk for AMGN (physician adoption, payer tiering) — approval alone won't guarantee rapid market share; likewise LLY valuation partly prices persistent pricing power that could be eroded by competition and payer moves. Reaction may be underdone: AMGN needs positive phase‑3 AND smooth payer access to rerate meaningfully, so near‑term implied upside should be traded via options. Historical parallel: insulin and statin markets where clinical parity led to rapid price competition and margin pressure; unintended consequence is volume growth but lower net prices.

Key Decisions for Investors

• Establish a 2–3% long position in AMGN (ticker: AMGN) in tranches over the next 6 weeks; set a 12% stop‑loss and a target sell at +25% within 12–18 months conditional on positive phase‑3 readout or clear FDA filing within 9–12 months.
• Implement a pair trade: long AMGN 2% / short LLY 1.25% to exploit the P/E gap (AMGN ~16x vs LLY ~32x); unwind if AMGN outperforms LLY by >30% or if AMGN forward P/E exceeds 20 persistently.
• Buy AMGN 18‑month LEAP calls (expiry ~Jan‑2028) ~15–25% OTM sized at 0.5–1% portfolio notional, or cheaper: a 12‑month call spread (10–20% OTM buy / 30–40% OTM sell) to leverage phase‑3 readout while capping premium; fund by selling LLY 12‑month call spreads (near‑ATM) sized to offset cost.
• Reduce exposure by 50% to small-cap GLP‑1 pure‑plays and reallocate into healthcare large caps (AMGN, ABBV, JNJ) over the next 3 months; monitor payer formulary changes and CMS policy updates for signs of net price compression (>10% change) before redeploying capital.